Obiettivo
In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal. In order to demonstrate the value of pluripotent stem cells for toxicology, the consortium will focus on four complementary aspects: Relevance –i.e. establishing and maintaining discrete cell phenotypes over long-term cultures; providing large versatility to adapt to assays of specific pathways. Efficiency –for i) automated cell production and differentiation, ii) cell engineering for differentiation and selection iii) multi-parametric toxicology using functional genomic, proteomic and bioelectronics. Extension –i.e. i) scalability through production of cells and technologies for industrial-scale assays, and ii) diversity of phenotypes (5 different tissues), and of genotypes (over 30 different donors). Normalization –validation and demonstration of reproducibility and robustness of cell-based assays on industrial-scale platforms, to allow for secondary development in the pharmaceutical and cosmetic industry. SCR&Tox will be intricately associated to other consortia of the “Alternative Testing” call, sharing biological, technological and methodological resources. Proof of concept of the proposed pluripotent stem cell-based assays for toxicology will be provided on the basis of toxicity pathways and test compounds identified by other consortia.
Campo scientifico
Invito a presentare proposte
FP7-HEALTH-2010-Alternative-Testing
Vedi altri progetti per questo bando
Meccanismo di finanziamento
CP-IP - Large-scale integrating projectCoordinatore
75654 Paris
Francia
Mostra sulla mappa
Partecipanti (14)
53127 Bonn
Mostra sulla mappa
413 46 Göteborg
Mostra sulla mappa
Partecipazione conclusa
75013 PARIS
Mostra sulla mappa
DD1 5JJ Dundee
Mostra sulla mappa
04109 Leipzig
Mostra sulla mappa
27005 EVREUX
Mostra sulla mappa
HG3 IPY Harrogate
Mostra sulla mappa
1049 Bruxelles / Brussel
Mostra sulla mappa
151 85 Sodertaelje
Mostra sulla mappa
17177 Stockholm
Mostra sulla mappa
26100 CREMONA
Mostra sulla mappa
Partecipazione conclusa
SW1W 9SZ London
Mostra sulla mappa
75015 PARIS
Mostra sulla mappa
LS2 7UE Leeds
Mostra sulla mappa